Announcements Trials
Browse Landscape

Status

Recruiting 70Active not recruiting 29Not yet recruiting 21Completed 8Terminated 4Suspended 3Enrolling by invitation 3Available 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Sarcoma 1Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplasms 1Mastocytosis, Systemic 1Leukemia, Mast-Cell 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1

Interventions

ulixertinib 1balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × Pancreatic Neoplasms × 30 days × Clear all
NCT04566393 2026-06-04

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡